Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

NCT02164006 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin's Lymphoma

Interventions

DRUG: TGR-1202 + brentuximab vedotin

Sponsor

TG Therapeutics, Inc.